May 7, 2021, Beijing, China- The 2021 CHC·CITIC Securities Healthcare Conference and the 10th China Healthcare Industry Investment and M&A CEO Summit were held in Shanghai recently, and announced the 2020 China Healthcare Industry Investment and Financing Honor list, InnoCare was awarded as the 2020 TOP10 Best Listed Biotech Companies.
Founded in 2015, InnoCare was successfully listed on the Hong Kong Stock Exchange on March 23, 2020, after five years of robust development, becoming the first biotech company listed on the Hong Kong Stock Exchange last year. Meanwhile, InnoCare has built up strong drug pipelines, and its BTK inhibitor orelabrutinib was approved for two indications in China on Dec. 25, 2020.
Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare said, “I am happy that InnoCare could contribute to the booming biotech industry. InnoCare has gathered a group of scientists with profound academic background who have developed over 10 innovative drugs in pipeline. It is a great milestone to get listed on the Hong Kong Stock Exchange. We will commit to our core value of ‘Science Drives Innovation’ and will develop more drugs to benefit patients.”
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.